RT Journal Article SR Electronic T1 Cardiac surveillance for anti-HER2 chemotherapy JF Cleveland Clinic Journal of Medicine JO Cleve Clin J Med FD Cleveland Clinic SP 110 OP 116 DO 10.3949/ccjm.88a.19150 VO 88 IS 2 A1 Patrick Collier A1 Muzna Hussain A1 Zoran B. Popovic A1 Brian P. Griffin YR 2021 UL http://www.ccjm.org/content/88/2/110.abstract AB Surveillance of left ventricular function, part of current US Food and Drug Administration recommendations for anti-human epidermal growth factor receptor 2 (anti-HER2) chemotherapy, is based on historical data involving patients who received concomitant anthracycline therapy, a key enhancer of cardiac risk. More recent anti-HER2 treatment data suggest that cardiotoxicity detected by screening is rare and usually benign for patients who do not have cardiovascular risk factors and are not taking an anthracycline. Because of the burden of repetitive echocardiography required for surveillance and the risk of false-positive results, potentially leading to discontinuing lifesaving treatment, we advocate for a more focused cardiac surveillance strategy.